Genitourinary cancers include the kidney, bladder, and prostate.

The Genitourinary Disease Site Group (GU DSG) produces evidence-based reports to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances. The titles of the reports produced to date by the GU DSG are listed below, together with links to the PDF versions of those reports.

Prostate Cancer

• Maximal Androgen Blockade for the Treatment of Metastatic Prostate Cancer
  3-1 PG: February 2003
  
  • Summary
  • Summary & Full Report
• Use of Strontium89 in Patients with Endocrine-Refractory Carcinoma of the Prostate Metastatic to Bone
  3-6 PG: October 2001 Update
  
  • Summary
  • Summary & Full Report
• The Use of Brachytherapy in T1 or T2 Prostate Cancer
  3-10 ES: May 2001 Update
  
  • Summary
  • Summary & Full Report
• The Use of Conformal Radiotherapy and the Selection of Radiation Dose in T1 or T2 Prostate Cancer
  3-11 PG:October 2002
  
  • Summary
  • Summary & Full Report
• The Use of Bisphosphonates in Men with Hormone-Refractory Prostate Cancer
  3-14 PG: January 2005
  
  • Summary
  • Summary & Full Report
• Non-hormonal Systemic Therapy in Men with Metastatic Hormone-refractory Prostate Cancer
  3-15 EBS: November 2005
  
  • Practice Guideline
  • Evidence-based Series
• High-intensity Focused Ultrasound for Prostate Cancer
  3-16 EBS: July 2009
  
  • Practice Guideline
  • Evidence-based Series
• Adjuvant Radiotherapy Following Radical Prostatectomy for Pathologic T3 or Margin-Positive Prostate Cancer
  3-17 EBS Version 2.2010: July 2010 Rewrite
  
  • Practice Guideline
  • Evidence-based Series

Bladder

• Use of Adjuvant Chemotherapy Following Cystectomy in Patients with Deep Muscle-Invasive Transitional Cell Carcinoma of the Bladder
  3-2-1 PG January 2003
  
  • Summary
  • Summary & Full Report
• Use of Neoadjuvant Chemotherapy in Transitional Cell Carcinoma of the Bladder
  3-2-2 PG Version 2.2005: May 2005 Rewrite
  
  • Summary
  • Summary & Full Report
• Use of Chemotherapy in Advanced Unresectable or Metastatic Transitional Cell Carcinoma of the Bladder or Urothelium
  3-12 PG: June 2002
  
  • Summary
  • Summary & Full Report

Kidney

• Interferon-alfa in the Treatment of Patients with Inoperable Locally Advanced or Metastatic Renal Cell Cancer
  3-8-1 EBS: May 2009
  
  • Practice Guideline
  • Evidence-Based Series
• Interleukin-2 in the Treatment of Patients with Unresectable or Metastatic Renal Cell Carcinoma
  3-8-2 EBS: June 2006
  
  • Practice Guideline
  • Evidence-Based Series
• The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma
  3-8-3 EBS: April 2006
  
  • Practice Guideline
  • Evidence-Based Series
• The Use of Inhibitors of Angiogenesis in Patients with Inoperable Locally Advanced or Metastatic Renal Cell Cancer
  3-8-4 EBS: April 2009
  
  • Practice Guideline
  • Evidence-Based Series

Testis

• Surveillance Programs for Early Stage Nonseminomatous Testicular Cancer
  3-5 PG: January 2001
  
  • Summary
  • Summary & Full Report
• Management of Stage I Seminoma
  3-18 EBS: January 2008
  
  • Practice Guideline
  • Evidence-Based Series
• Management of Stage I Nonseminomatous Testicular Cancer
  3-19 PG: February 2008
  
  • Practice Guideline
  • Evidence-Based Series